Sonus/Abbott
This article was originally published in The Gray Sheet
Executive Summary
Enter agreement under which Abbott will manufacture privately held Sonus Pharmaceuticals' first product line, the EchoGen echocardiology and general radiology ultrasound contrast agents, according to a July 13 press release. Terms of the deal were not disclosed. Sonus plans to market the agents itself in the U.S. and is in discussions with more than one firm for international distribution. Sonus plans to begin EchoGen clinical trials by the end of the year....